Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA

Expert Review of Anti-infective Therapy
Tina Q Tan

Abstract

Serious and invasive infections caused by Streptococcus pneumoniae continue to be a major cause of morbidity and mortality worldwide. The introduction of a hepatavalent pneumococcal conjugate vaccine (PCV7) in 2000 in the USA has had a significant impact on decreasing the incidence of serious and invasive pneumococcal disease in all age groups, especially in children under 2 years of age. However, the emergence of replacement nonvaccine pneumococcal serotypes (e.g., 19A, 3, 15 and 33) has resulted in an increase in the incidence of serious and invasive infections. The scope of disease caused by these emerging serotypes is not fully known, and the development of other pneumococcal conjugate vaccines is critical in order to control the amount of invasive disease that is currently being seen. The objective of this review is to discuss the current epidemiology of serious and invasive pneumococcal infections post-PCV7 introduction in the USA and review the pneumococcal vaccines that are in development.

References

Nov 21, 1991·The New England Journal of Medicine·E D ShapiroJ D Clemens
Jan 1, 1991·American Journal of Diseases of Children·N M Jacobs
Feb 3, 1989·JAMA : the Journal of the American Medical Association·M DavidsonW L Heyward
Aug 24, 1995·The New England Journal of Medicine·J HofmannR F Breiman
May 1, 1993·The Pediatric Infectious Disease Journal·L J BaraffD L Schriger
Jun 1, 1996·The Journal of Pediatrics·I R Friedland
Jun 1, 1997·Pediatric Annals·S Black, H Shinefield
Feb 12, 1998·The New England Journal of Medicine·A SchuchatB A Perkins
Jun 13, 1998·Annals of Emergency Medicine·N KuppermannD M Jaffe
Aug 10, 1999·The Pediatric Infectious Disease Journal·F GhaffarG H McCracken
Sep 24, 1999·The Pediatric Infectious Disease Journal·H R ShinefieldJ Hansen
Apr 13, 2000·Pediatric Clinics of North America·L G Rubin
Oct 13, 2000·Journal of General Internal Medicine·J A BrandenburgM J Fine
Apr 17, 2001·The Pediatric Infectious Disease Journal·T WuorimaaH Käyhty
Jun 22, 2002·The Pediatric Infectious Disease Journal·Taneli PuumalainenHanna Nohynek
May 2, 2003·The New England Journal of Medicine·Cynthia G WhitneyUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
Oct 3, 2003·The New England Journal of Medicine·Keith P KlugmanUNKNOWN Vaccine Trialists Group
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Faryal GhaffarGeorge H McCracken
Oct 27, 2005·JAMA : the Journal of the American Medical Association·Catherine A LexauUNKNOWN Active Bacterial Core Surveillance Team
Nov 4, 2005·The Journal of Infectious Diseases·Rekha PaiUNKNOWN Active Bacterial Core Surveillance Team
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Samir S Shah, Adam J Ratner
Mar 3, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrew P SteenhoffKarin L McGowan
Mar 29, 2006·The Pediatric Infectious Disease Journal·Blanca E GonzalezUNKNOWN U.S. Pediatric Multicenter Pneumococcal Surveillance Group
Apr 7, 2006·The New England Journal of Medicine·Moe H KyawUNKNOWN Active Bacterial Core Surveillance of the Emerging Infections Program Network
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Katherine A PoehlingWilliam Schaffner
Jun 8, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eugene V MillarMathuram Santosham
Dec 7, 2007·Archives of Pediatrics & Adolescent Medicine·Fangjun ZhouJ Pekka Nuorti

❮ Previous
Next ❯

Citations

Nov 19, 2011·The Pediatric Infectious Disease Journal·Salome HugUlrich Heininger
Aug 7, 2010·MBio·Antonio Cassone, Rino Rappuoli
Dec 22, 2012·Expert Opinion on Pharmacotherapy·Susanna Esposito, Nicola Principi
Feb 22, 2011·Expert Review of Vaccines·Mark H RozenbaumEelko Hak
Apr 26, 2011·Medicina clínica·Carlos Rodrigo Gonzalo de Liria
Sep 12, 2013·Vaccine·Susanna EspositoNicola Principi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Related Papers

American Journal of Epidemiology
Marcelo A CostaJonathan A Finkelstein
JAMA : the Journal of the American Medical Association
K A RobinsonActive Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network
Journal of the American Geriatrics Society
Benjamin A KupronisActive Bacterial Core Surveillance Team
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Ron Dagan
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
J D KellnerDavid W Scheifele
© 2021 Meta ULC. All rights reserved